<?xml version="1.0" encoding="UTF-8"?>
<p id="par0525">The strength of the immune response in transiently infected healthy carriers, in symptomatic individuals who are cured, and the length of time individuals remain immune to re-infection also need to be better understood. A major uncertainty stems from the lack of regression from early cures, but lessons can be learned from data on the duration of antibody effectiveness against SARS-CoV and MERS-CoV, which are related viruses 
 <xref rid="bib0075" ref-type="bibr">[5]</xref>.
</p>
